Press releaseGlobe Newswire
NewcelX AG
NCEL · NASDAQ
$2.61−$0.02 (−0.76%)TodayMarket closed ·
Prev close $2.63
Latest news
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releaseGlobe Newswire
NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing
- Press releaseGlobe Newswire
NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio
- Press releaseGlobe Newswire
NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board
- Press releasePRNewswire
The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy
- News
NewcelX Completes Type B Pre-IND Meeting With FDA; Administration Provided Constructive Feedback And Alignment On Proposed Strategy
- Press releaseGlobe Newswire
NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
- Press releaseGlobe Newswire
NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform
- Press releaseGlobe Newswire
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- Press releaseGlobe Newswire
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- Press releasePRNewswire
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes
- Press releasePRNewswire
NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy
- Press releasePRNewswire
NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences
- Press releasePRNewswire
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression
- Press releasePRNewswire
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- Press releasePRNewswire
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China
- Press releasePRNewswire
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute
- Press releasePRNewswire
NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- Press releasePRNewswire
NewcelX CEO Issues Letter to Shareholders
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- Press releasePRNewswire
NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- NewsAvi Kapoor
Why Lucas GC Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket
- Press releasePRNewswire
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.